The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors

Abstract Background With the availability of first disease-modifying treatments, evidence on costs across the entire Alzheimer's Continuum, especially for early disease stages, becomes increasingly important to inform healthcare planning, resource allocation, and policy decisions. This study assesse...

Descrición completa

Detalles Bibliográficos

Principais autores:	Eva Gläser, Ingo Kilimann, Moritz Platen, Wolfgang Hoffmann, Frederic Brosseron, Katharina Buerger, Marie Coenjaerts, Emrah Düzel, Michael Ewers, Klaus Fliessbach, Ingo Frommann, Maria Gemenetzi, Wenzel Glanz, Julian Hellmann-Regen, Enise I. Incesoy, Daniel Janowitz, Frank Jessen, Oliver Peters, Josef Priller, Alfredo Ramirez, Anja Schneider, Annika Spottke, Eike Jakob Spruth, Stefan Teipel, Michael Wagner, Bernhard Michalowsky
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2025-06-01
Series:	Alzheimer’s Research & Therapy
Assuntos:	Dementia Cognition Subjective cognitive decline Mild cognitive impairment Alzheimer’s disease Apolipoprotein E
Acceso en liña:	https://doi.org/10.1186/s13195-025-01785-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!